Lineage Cell TherapeuticsLCTX
LCTX
About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Employees: 75
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
131% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 16
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
8% more funds holding
Funds holding: 114 [Q3] → 123 (+9) [Q4]
1.86% less ownership
Funds ownership: 50.44% [Q3] → 48.58% (-1.86%) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
38% less capital invested
Capital invested by funds: $86.2M [Q3] → $53.8M (-$32.4M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
196%
upside
Avg. target
$4.67
590%
upside
High target
$9
1,231%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 23% 1-year accuracy 93 / 411 met price target | 1,231%upside $9 | Buy Reiterated | 11 Feb 2025 |
D. Boral Capital Jason Kolbert 36% 1-year accuracy 85 / 239 met price target | 196%upside $2 | Buy Maintained | 11 Feb 2025 |
Maxim Group Michael Okunewitch 44% 1-year accuracy 4 / 9 met price target | 344%upside $3 | Buy Maintained | 10 Jan 2025 |
Financial journalist opinion
Based on 5 articles about LCTX published over the past 30 days
Neutral
Business Wire
1 week ago
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery Syste.
Neutral
Business Wire
2 weeks ago
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025. Interested parties can view a re.
Positive
24/7 Wall Street
2 weeks ago
Insiders Are Scooping Up These 5 Stocks Now
Since the beginning of the year, the number of notable insider purchases has been lower than usual.
Positive
Zacks Investment Research
3 weeks ago
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Neutral
Business Wire
3 weeks ago
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an addit.
Neutral
Business Wire
1 month ago
Lineage Cell Therapeutics Issues Letter to Stockholders
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company's recent achievements and outlook for 2025. Dear Fellow Shareholders, We hope you had a restful holiday season and wish you a happy new year. As we look at our plans for the new year, we want to update you on our recent progress and.
Positive
Zacks Investment Research
2 months ago
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Business Wire
3 months ago
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the “common warrants”) to purchase an aggregate of up to 39,473,688 of Lineage's common shares.
Negative
Zacks Investment Research
3 months ago
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
Business Wire
3 months ago
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. (“Broadwood”), an affiliate of Neal Bradsher, a member of Lineage's board of directors, for the purchase and sale of up to an aggregate of 39,473,688.
Charts implemented using Lightweight Charts™